I. H. Lin, M. L. Ho, H. Y. Chen, and H. S. Lee, Smoking, Green Tea Consumption, Genetic Polymorphisms in the Insulin-Like Growth Factors and Lung Cancer Risk, PLoS ONE, vol.170, issue.6, p.30951, 2012.
DOI : 10.1371/journal.pone.0030951.t005

C. L. Sun, J. M. Yuan, W. P. Koh, and M. C. Yu, Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies, Carcinogenesis, vol.27, issue.7, pp.1310-1315, 2006.
DOI : 10.1093/carcin/bgi276

Y. J. Surh, Cancer chemoprevention with dietary phytochemicals, Nature Reviews Cancer, vol.3, issue.10, pp.768-780, 2003.
DOI : 10.1038/nrc1189

S. C. Renaud, R. Gueguen, J. Schenker, and A. Houtaud, Alcohol and Mortality in Middle-Aged Men from Eastern France, Epidemiology, vol.9, issue.2, pp.184-188, 1998.
DOI : 10.1097/00001648-199803000-00014

D. Delmas, E. Solary, and N. Latruffe, Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe, Current Medicinal Chemistry, vol.18, issue.8, pp.1100-1121, 2011.
DOI : 10.2174/092986711795029708

J. A. Baur and D. A. Sinclair, Therapeutic potential of resveratrol: the in vivo evidence, Nature Reviews Drug Discovery, vol.24, issue.6, pp.493-506, 2006.
DOI : 10.1038/nrd2060

M. E. Juan, I. Alfaras, and J. M. Planas, Colorectal cancer chemoprevention by trans-resveratrol, Pharmacological Research, vol.65, issue.6, pp.584-591, 2012.
DOI : 10.1016/j.phrs.2012.03.010

S. Ulrich, S. M. Loitsch, O. Rau, and A. Von-knethen, Peroxisome Proliferator-Activated Receptor ?? as a Molecular Target of Resveratrol-Induced Modulation of Polyamine Metabolism, Cancer Research, vol.66, issue.14, pp.7348-7354, 2006.
DOI : 10.1158/0008-5472.CAN-05-2777

I. Alfaras, M. E. Juan, and J. M. Planas, Resveratrol Reduces Precancerous Colonic Lesions in Dimethylhydrazine-Treated Rats, Journal of Agricultural and Food Chemistry, vol.58, issue.13, pp.8104-8110, 2010.
DOI : 10.1021/jf100702x

L. Tessitore, A. Davit, I. Sarotto, and G. Caderni, Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21CIP expression, Carcinogenesis, vol.21, issue.8, pp.1619-1622, 2000.
DOI : 10.1093/carcin/21.5.619

K. R. Patel, V. A. Brown, D. J. Jones, and R. G. Britton, Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients, Cancer Research, vol.70, issue.19, pp.7392-7399, 2010.
DOI : 10.1158/0008-5472.CAN-10-2027

D. Colin, A. Gimazane, G. Lizard, and J. C. Izard, Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells, International Journal of Cancer, vol.32, issue.Part 2, pp.2780-2788, 2009.
DOI : 10.1002/ijc.24264
URL : https://hal.archives-ouvertes.fr/hal-00374912

A. K. Marel, G. Lizard, J. C. Izard, N. Latruffe, and D. Delmas, Inhibitory effects oftrans-resveratrol analogs molecules on the proliferation and the cell cycle progression of human colon tumoral cells, Molecular Nutrition & Food Research, vol.92, issue.5, pp.538-548, 2008.
DOI : 10.1002/mnfr.200700185

D. Delmas, C. Rebe, S. Lacour, and R. Filomenko, Resveratrol-induced Apoptosis Is Associated with Fas Redistribution in the Rafts and the Formation of a Death-inducing Signaling Complex in Colon Cancer Cells, Journal of Biological Chemistry, vol.278, issue.42, pp.41482-41490, 2003.
DOI : 10.1074/jbc.M304896200

D. Colin, E. Limagne, S. Jeanningros, and A. Jacquel, Endocytosis of Resveratrol via Lipid Rafts and Activation of Downstream Signaling Pathways in Cancer Cells, Cancer Prevention Research, vol.4, issue.7, pp.1095-1106, 2011.
DOI : 10.1158/1940-6207.CAPR-10-0274

M. Gurnell, J. M. Wentworth, M. Agostini, and M. Adams, A Dominant-negative Peroxisome Proliferator-activated Receptor gamma (PPARgamma ) Mutant Is a Constitutive Repressor and Inhibits PPARgamma -mediated Adipogenesis, Journal of Biological Chemistry, vol.275, issue.8, pp.5754-5759, 2000.
DOI : 10.1074/jbc.275.8.5754

D. Delmas, P. Passilly-degrace, B. Jannin, M. C. Malki, and N. Latruffe, Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells, International Journal of Molecular Medicine, vol.10, pp.193-199, 2002.
DOI : 10.3892/ijmm.10.2.193

D. Delmas, C. Rebe, O. Micheau, and A. Athias, Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells, Oncogene, vol.23, issue.55, pp.8979-8986, 2004.
DOI : 10.1038/sj.onc.1208086

V. Aires, E. Limagne, A. K. Cotte, and N. Latruffe, Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death, Molecular Nutrition & Food Research, vol.434, issue.7, 2013.
DOI : 10.1002/mnfr.201200766

D. Delmas, B. Jannin, M. C. Malki, and N. Latruffe, Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines., Oncology Reports, vol.7, pp.847-852, 2000.
DOI : 10.3892/or.7.4.847

J. M. Seargent, E. A. Yates, and J. H. Gill, activation, British Journal of Pharmacology, vol.286, issue.8, pp.933-937, 2004.
DOI : 10.1038/sj.bjp.0705973

L. M. Leesnitzer, D. J. Parks, R. K. Bledsoe, and J. E. Cobb, Functional Consequences of Cysteine Modification in the Ligand Binding Sites of Peroxisome Proliferator Activated Receptors by GW9662, Biochemistry, vol.41, issue.21, pp.6640-6650, 2002.
DOI : 10.1021/bi0159581

E. Mueller, M. Smith, P. Sarraf, and T. Kroll, Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer, Proceedings of the National Academy of Sciences, vol.97, issue.20, pp.10990-10995, 2000.
DOI : 10.1073/pnas.180329197

A. Cerbone, C. Toaldo, R. Minelli, and E. Ciamporcero, Rosiglitazone and AS601245 Decrease Cell Adhesion and Migration through Modulation of Specific Gene Expression in Human Colon Cancer Cells, PLoS ONE, vol.56, issue.6, p.40149, 2012.
DOI : 10.1371/journal.pone.0040149.s001

M. Jang, L. Cai, G. O. Udeani, and K. V. Slowing, Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes, Science, vol.275, issue.5297, pp.218-220, 1997.
DOI : 10.1126/science.275.5297.218

N. Ahmad, S. K. Katiyar, and H. Mukhtar, Antioxidants in Chemoprevention of Skin Cancer
DOI : 10.1159/000060662

P. A. Kroon, A. Iyer, P. Chunduri, V. Chan, and L. Brown, The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential, Current Medicinal Chemistry, vol.17, issue.23, pp.2442-2455, 2010.
DOI : 10.2174/092986710791556032

A. Shih, S. Zhang, H. J. Cao, and S. Boswell, Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha, Mol Cancer Ther, vol.3, pp.1355-1364, 2004.

H. Y. Lin, A. Shih, F. B. Davis, and H. Y. Tang, Resveratrol Induced Serine Phosphorylation Of p53 Causes Apoptosis In A Mutant p53 Prostate Cancer Cell Line, The Journal of Urology, vol.168, issue.2, pp.748-755, 2002.
DOI : 10.1016/S0022-5347(05)64739-8

A. P. Heaney, M. Fernando, and S. Melmed, PPAR-?? receptor ligands: novel therapy for pituitary adenomas, Journal of Clinical Investigation, vol.111, issue.9, pp.1381-1388, 2003.
DOI : 10.1172/JCI200316575

R. Yoshimura, M. Matsuyama, Y. Segawa, and T. Hase, Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists, International Journal of Cancer, vol.115, issue.5, pp.597-602, 2003.
DOI : 10.1002/ijc.10980

L. Michalik, B. Desvergne, and W. Wahli, Peroxisome-proliferator-activated receptors and cancers: complex stories, Nature Reviews Cancer, vol.4, issue.1, pp.61-70, 2004.
DOI : 10.1038/nrc1254

J. M. Peters, Y. M. Shah, and F. J. Gonzalez, The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention, Nature Reviews Cancer, vol.74, pp.181-195, 2012.
DOI : 10.1038/nrc3214

H. P. Koeffler, Peroxisome proliferator-activated receptor gamma and cancers, Clin Cancer Res, vol.9, pp.1-9, 2003.

P. Sarraf, E. Mueller, D. Jones, and F. J. King, Differentiation and reversal of malignant changes in colon cancer through PPAR??, Nature Medicine, vol.11, issue.9, pp.1046-1052, 1998.
DOI : 10.1056/NEJM199411033311803

C. Lamers, M. Schubert-zsilavecz, and D. Merk, Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008???present), Expert Opinion on Therapeutic Patents, vol.22, issue.2, pp.803-841, 2012.
DOI : 10.1038/nrd1551

S. J. Roberts-thomson, Peroxisome proliferator-activated receptors in tumorigenesis: Targets of tumour promotion and treatment, Immunology and Cell Biology, vol.26, issue.4, pp.436-441, 2000.
DOI : 10.1038/2036

M. A. Bae and B. J. Song, Critical Role of c-Jun N-Terminal Protein Kinase Activation in Troglitazone-Induced Apoptosis of Human HepG2 Hepatoma Cells, Molecular Pharmacology, vol.63, issue.2, pp.401-408, 2003.
DOI : 10.1124/mol.63.2.401

B. Farrow and B. M. Evers, Activation of PPAR?? increases PTEN expression in pancreatic cancer cells, Biochemical and Biophysical Research Communications, vol.301, issue.1, pp.50-53, 2003.
DOI : 10.1016/S0006-291X(02)02983-2

M. Nagamine, T. Okumura, S. Tanno, and M. Sawamukai, PPARgamma ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells, Cancer Science, vol.113, issue.4, pp.338-343, 2003.
DOI : 10.1016/S0014-2999(00)00758-5

Q. Zhang, H. Zhou, S. Zhai, and B. Yan, Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities, Current Pharmaceutical Design, vol.16, issue.16, pp.1826-1842, 2010.
DOI : 10.2174/138161210791208983

S. Wei, J. Yang, S. L. Lee, S. K. Kulp, and C. S. Chen, PPAR??-independent antitumor effects of thiazolidinediones, Cancer Letters, vol.276, issue.2, pp.119-124, 2009.
DOI : 10.1016/j.canlet.2008.08.008

J. H. Choi, A. S. Banks, T. M. Kamenecka, and S. A. Busby, Antidiabetic actions of a non-agonist PPAR?? ligand blocking Cdk5-mediated phosphorylation, Nature, vol.53, issue.7365, pp.477-481, 2011.
DOI : 10.1038/nature10383